Plain-English translation of NCT06367465 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hepatitis C research guide →This trial is testing whether , a hepatitis C medication, can be safely given to pregnant people to treat their hepatitis C infection. Currently, there is limited information about using this medication during pregnancy, and this study aims to see if it is feasible and acceptable for pregnant patients to start treatment early.
Hepatitis C can affect both pregnant people and their babies, but there has been little research on whether this safe and effective medication can be used during pregnancy. This study will help doctors understand if the medication works and if pregnant people are willing to take it.
You likely qualify if…
You likely don't qualify if…
You would attend four in-person study visits over about 8–12 weeks. At your first visit, you'll receive information about hepatitis C treatment, have blood tests done (which are routine for all pregnant people), and start the medication. You'll return for visits while taking the medication, at the end of treatment, and four weeks after finishing to have blood tests and answer questions about how well you took your medication. Researchers will also check your medical records for up to one year after you join to see how you and your baby are doing.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States
Washington University School of Medicine
Enrollment target
~50 participants
Started
February 2024
Primary completion
December 2026
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tracey Bach, MBA
Washington University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.